either ccA (less aggressive) or ccB (more aggressive) molecular subtypes. Age-and sex-adjusted logistic regression models estimated associations between sarcopenia and molecular subtype separately for obese and non-obese patients. Statistical significance was regarded as a p-value of<0.05.
INTRODUCTION AND OBJECTIVES: Current standards of tumor assessment often do not provide a comprehensive evaluation for the optimal management of renal cancer patients. While genomic and epigenomic biomarkers have shown improvements in patient risk classification, the heterogeneity of renal tumors on imaging can confound assessment. The objective was to investigate the association of contrast-enhanced computed tomography (CECT)-based radiomics obtained from clinical imaging features with DNA-methylation (DNAm) features that predict aggressive clear cell renal carcinoma (ccRCC).
METHODS: In this IRB-approved retrospective study, 29 patients (15 aggressive and 14 non-aggressive) with pathologically confirmed ccRCC and a pre-operative multiphase CECT were identified. An abdominal radiologist supervised the segmentation of each tumor from a clinical, standard of care CT study on a dedicated workstation. We evaluated 6 different types of texture extraction techniques from every phase of the imaging study. Genome-wide DNAm profiles were generated from tumor tissue extracted from the same patients using the Infinium Methylation EPIC array. We correlated all 1495 radiomic features processed with 97 DNAm features selected based on their strength of separating non-aggressive from aggressive renal tumors and non-aggressive from normal kidney in 281 ccRCC from the Cancer Genome Atlas. We computed Pearson and Spearman correlations depending on data distribution, for all possible pairs of radiomics and DNAm features. The results were summarized within each of the 6 radiomics categories by the percent of correlation coefficients attaining nominal p<0.05 for each DNAm feature (suggestive of a positive signal) and presented in a heatmap (Figure 1) .
RESULTS: There were significant (p<0.05) correlations between the selected epigenetic features and the radiomics features. Gray-level difference method (GLDM) 2D and 3D were shown having a strong signal in the correlation with cg12697139 and cg16973527. In general, second-order statistical texture method: GLDM was seen to have the most correlation with selected epigenetic nodes.
CONCLUSIONS: To our knowledge, this is the first study to correlate epigenomic profiles with CECT based radiomics features of renal masses. We plan to validate the finding in a larger patient cohort study. (Gatto et al, Cell Reports, 2016) . However, it is unknown if GAG scores can detect RCC in earlier stages or non-ccRCC histologies.
METHODS: In this retrospective study, pre-operative plasma GAG levels from 162 RCC patients were compared to 19 healthy controls between 5/2011-2/2014. GAG scores were generated using 19 pre-specified properties and measured using capillary electrophoresis with laser induced fluorescence. GAG profile differences in RCC versus healthy controls were assessed using unsupervised clustering methods. A discovery set of 68 RCC vs. 19 healthy samples were first analyzed to update the historical GAG score. The new GAG score accuracy in RCC detection versus healthy subjects was validated using the remaining 94 RCC samples. RESULTS: Median age was similar between RCC and healthy cohorts, 60 years (IQR: 52-67) vs. 55 years (IQR: 50-60), respectively. In the RCC cohort, 113 (70%) were ccRCC and 49 (30%) non-ccRCC. RCC stage included 86 (53%) pT1, 66 (41%) pT2-3, and 12 (7%) pT4. GAG profiles in RCC clustered separately from healthy volunteers ( Figure 1A ). In the first discovery set (n¼68), the GAG score distinguished RCC from healthy subjects with an AUC equal to 0.999, 94.7% specificity and 100% sensitivity at an optimal cut-off equal to 0.87 ( Figure 1B ). In the validation set (n¼94), the GAG score achieved an AUC equal to 0.994 (95% CI: 0.985 -1) and 95.7% sensitivity ( Figure  1B) . GAG scores did not correlate with age or gender. GAG scores were elevated in all RCC samples compared to normal controls, irrespective and uncorrelated to stage, grade or histology.
CONCLUSIONS: Plasma GAG scores are measurably elevated in RCC compared to healthy individuals. It was possible to detect RCC irrespective of stage or histology with 95.7% sensitivity. GAG scores did not correlate with pathologic stage, grade, or histology. These findings suggest that GAG alterations occur early in tumor formation but are likely independent of progression. These findings warrant prospective validation to assess the clinical utility of pre-operative GAG scores as biomarkers for RCC. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e959
